GlassScriptPhysician profile
Molly L Cahill
NPI 1336104702
$21,663.73
in general payments reported to CMS, 2019-2025
21 companies · $5,766 in 2025
The $5,766 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,365 · 2022: $7,651 · 2023: $1,216 · 2024: $666 · 2025: $5,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,850 · Food and Beverage: $1,890 · Consulting Fee: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,850.00 |
| Food and Beverage | $1,890.44 |
| Consulting Fee | $907.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11,567.04 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Eli Lilly and Company | $4,930.00 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,205.80 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $1,032.15 | 2024-2025 | Rivfloza, Ozempic |
| Astrazeneca Pharmaceuticals LP | $515.63 | 2021-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $300.71 | 2021-2025 | Vafseo |
| Travere Therapeutics, INC. | $146.11 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.70 | 2021 | |
| Vifor Pharma, INC. | $131.42 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $117.24 | 2021 | |
| Calliditas Therapeutics US INC. | $116.59 | 2024 | |
| Daiichi Sankyo INC. | $110.98 | 2021 | |
| Nxstage Medical, INC. | $82.95 | 2021 | |
| Opko Pharmaceuticals, LLC | $53.49 | 2021-2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $53.17 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.90 | 2024-2025 | Ibsrela |
| Bard Peripheral Vascular, INC. | $37.05 | 2021 | |
| Amicus Therapeutics, INC. | $22.65 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.29 | 2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $19.64 | 2025 | Livtencity |
| Horizon Therapeutics Plc | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Cahill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.